Role of topical therapy: Imiquimod

Elise Ng, Vicki Levine

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

The gold standard for treatment of lentigo maligna is complete surgical excision. Second-line non-surgical modalities include radiotherapy, laser therapy, and topical therapies. Evidence for the use of various topical agents, including tretinoin, azelaic acid, and 5-fluorouracil, is limited. The greatest evidence exists for imiquimod 5 % cream, which has been investigated in multiple case series and studies. Topical imiquimod appears to be effective in a subset of cases, but clinical response is unpredictable and guidelines for monitoring and follow-up remain to be established. As such, its role in the treatment of lentigo maligna remains controversial and additional studies with higher quality evidence are needed.

Original languageEnglish (US)
Title of host publicationLentigo Maligna Melanoma
Subtitle of host publicationChallenges in Diagnosis and Management
PublisherSpringer International Publishing
Pages139-151
Number of pages13
ISBN (Electronic)9783319437873
ISBN (Print)9783319437859
DOIs
StatePublished - Jan 1 2016
Externally publishedYes

Keywords

  • Imiquimod
  • Immune response modifier
  • Lentigo maligna
  • Melanoma
  • Melanoma in-situ
  • Topical immunomodulator

ASJC Scopus subject areas

  • Medicine(all)

Fingerprint Dive into the research topics of 'Role of topical therapy: Imiquimod'. Together they form a unique fingerprint.

Cite this